Axsome Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.65
Dividend & YieldN/A$ (N/A)
Beta 1.75
Market capitalization 3.08B
Operating cash flow -117.79M
ESG Scores unknown

Company description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio3.75
Working Capital-2.06
Return On Equity-8.34
Debt To Equity3.14
Fixed Asset Ratio17.37
Fixed Interest Cover-21.89

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 251.79k 7.26M 2.56M -354.69k
Total Cashflows From Investing Activities -32.7k -16.12k -45.89k -307.55k
Net Borrowings -3.33M 12.76M 28.34M
Total Cash From Financing Activities 10.03M 252.39M 42.41M 11.13M
Change To Operating Activities 1.27M 7.91M -2.15M 679.48k
Issuance Of Stock 13.39M 239.63M 15.18M 11.61M
Net Income -30.97M -68.35M -102.9M -130.4M
Change In Cash -20.05M 206M -36.09M -97.4M
Effect Of Exchange Rate
Total Cash From Operating Activities -30.05M -46.38M -78.46M -108.23M
Depreciation 48.94k 37.33k 77.72k 1.16M
Change To Account Receivables
Other Cashflows From Financing Activities -26k -1.1M -1.1M -309.34k
Change To Netincome -1.04M 6.12M 23.17M 19.62M
Capital Expenditures -32.7k -16.12k -45.89k -307.55k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 23.28M 53.51M 59.99M 58.06M
Income Before Tax -30.97M -68.35M -102.9M -130.4M
Net Income -30.97M -68.35M -102.9M -130.4M
Selling General Administrative 9.35M 13.6M 28.9M 66.65M
Gross Profit
Ebit -32.63M -67.11M -88.89M -124.71M
Operating Income -32.63M -67.11M -88.89M -124.71M
Interest Expense -1.13M -1.24M -2.57M -5.7M
Income Tax Expense
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet 1.66M -1.24M -14.01M -5.7M
Net Income From Continuing Ops -30.97M -68.35M -102.9M -130.4M
Net Income Applicable To Common Shares -30.97M -68.35M -102.9M -130.4M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 14.44M 41.83M 72.34M 72.15M
Total Stockholder Equity 937.92k 178.72M 113.79M 15.63M
Other Current Liabilities
Total Assets 15.38M 220.55M 186.13M 87.79M
Common Stock 3.01k 3.69k 3.74k 3.78k
Other Current Assets
Retained Earnings -107.55M -175.9M -278.8M -409.2M
Treasury Stock
Cash 13.97M 219.97M 183.88M 86.47M
Total Current Liabilities 10.82M 24.49M 23.44M 23.07M
Other Stockholder Equity
Property, Plant, and Equipment 51.83k 30.62k 1.79M 944.01k
Total Current Assets 15.22M 220.38M 184.02M 86.52M
Net Tangible Assets 937.92k 178.72M 113.79M 15.63M
Net Receivables
Accounts Payable 3.69M 10.94M 13.5M 13.15M


Insider Transactions

Here are the insider transactions of stock shares related to Axsome Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
COLEMAN MARK HConversion of Exercise of derivative security at price 1.30 per share.D2022-03-15Director3.5k
JEFFS ROGER APurchase at price 37.30 per share.D2021-11-19Director3.95k
COLEMAN MARK HPurchase at price 35.07 - 35.10 per share.I2021-11-18Director1.43k
PIZZIE NICK CPAPurchase at price 34.30 - 35.50 per share.D/I2021-11-18Chief Financial Officer955
SAAD MARK EPurchase at price 34.40 - 34.53 per share.D/I2021-11-17Director3.3k
COLEMAN MARK HPurchase at price 58.15 per share.I2021-05-12Director500

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Axsome Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Axsome Therapeutics Inc

Here is the result of two systematic investment strategies applied to Axsome Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Axsome Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Axsome Therapeutics Inc:

Axsome Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 209.22% on the backtest period.

Performance at glance

Performance

209.22 %

Latent gain

3535.93 $

Invested capital

1690.07 $

Annualized return

51.03 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Axsome Therapeutics Inc

This is the result of two momentum investment strategies applied to Axsome Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Axsome Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Axsome Therapeutics Inc:

Axsome Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 379.41% of return on Axsome Therapeutics Inc. That represents 14221.17$ of latent gain with 3748.24$ of employed capital.
  • The second momentum investment strategy would give 542.52% of return on Axsome Therapeutics Inc. That represents 18770.71$ of latent gain with 3459.9$ of employed capital.
Performance at glance (1Q Momentum)

Performance

379.41 %

Latent gain

14221.17 $

Invested capital

3748.24 $

Annualized return

5.71 %
Performance at glance (2Q Momentum)

Performance

542.52 %

Latent gain

18770.71 $

Invested capital

3459.9 $

Annualized return

149.87 %

Momentum equity curve on Axsome Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Axsome Therapeutics Inc:

Axsome Therapeutics Inc momentum equity

Note: the dividends potentially given by Axsome Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Axsome Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Axsome Therapeutics Inc since the beginning:

Axsome Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Axsome Therapeutics Inc

Buy the dip entry openings on Axsome Therapeutics Inc

Axsome Therapeutics Inc

The performance achieved by the robo-advisor on Axsome Therapeutics Inc is 11.99%. That represents 60.24$ of latent gain with 502.56$ of employed capital. The following chart shows Axsome Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Axsome Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

11.99 %

Latent gain

60.24 $

Invested capital

502.56 $

Annualized return

5.71 %

Equity curve of the strategy applied to Axsome Therapeutics Inc

The following chart shows the result of the investment strategy applied to Axsome Therapeutics Inc:

Axsome Therapeutics Inc

Note: the dividends potentially given by Axsome Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Axsome Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Axsome Therapeutics Inc:

Axsome Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Axsome Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Axsome Therapeutics Inc.

Equity curve comparison on Axsome Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Axsome Therapeutics Inc investment strategy comparison

Employed capital comparison on Axsome Therapeutics Inc

Axsome Therapeutics Inc investment comparison

Performance comparison on Axsome Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 209.22% 3535.93$ 1690.07$ 51.03%
Momentum 1 quarter 379.41% 14221.17$ 3748.24$ 98.29%
Momentum 2 quarters 542.52% 18770.71$ 3459.9$ 149.87%
Non-directional 11.99% 60.24$ 502.56$ 5.71%
Annualized return comparison

Automatic investment

51.03 %

Momentum 1Q

149.87 %

Momentum 2Q

149.87 %

Non-directional

5.71 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Axsome Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Axsome Therapeutics Inc

  • Most correlated stocks last 3 months

  • Buckle Inc
  • Axsome Therapeutics Inc
  • Hello Group Inc
  • DREAM INTL
  • Noah Holdings Ltd
  • HPC HOLDINGS

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Axsome Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Axsome Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Axsome Therapeutics Inc
    Country United States
    City New York
    Address 22 Cortlandt Street
    Phone 212 332 3241
    Website www.axsome.com
    FullTime employees 352
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker AXSM
    Market www.nasdaq.com

    Axsome Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown